Back to List View Graph View

EGFR

EGFR is a gene encoding a transmembrane receptor tyrosine kinase.

Where the papers sit

126 papers from the last 6 months study EGFR directly · updated from PubMed 16 Nov 2026

  • EGFR-Targeted Solid Tumors

    EGFR-directed therapy is being extended across head and neck, esophageal, colorectal, renal, breast and other solid tumors. Antibodies such as panitumumab, nimotuzumab and amivantamab are being combined with checkpoint blockade or chemotherapy, while photoimmunotherapy and EGFRvIII-specific CAR-T approaches seek more selective killing. Tumor subtype, receptor co-expression and the microenvironment repeatedly determine response. The field is moving toward biomarker-selected combinations, but activity remains uneven across tumor types.

    53 papers · 42.1%

  • EGFR-Mutant Lung Cancer

    Osimertinib remains the treatment backbone for EGFR-mutated non-small cell lung cancer, with progression-free survival shaped by mutation subtype, TP53 co-mutation and EGFR amplification. Afatinib, firmonertinib and amivantamab-based regimens broaden options across uncommon mutations and progression. Resistance is increasingly linked to small-cell transformation, BRAF fusions, drug-tolerant persisters and ULK1 or TROP2 biology. Repeat molecular profiling and combination strategies are moving to the forefront.

    47 papers · 37.3%

  • Computational Drug Discovery

    Molecular docking and dynamics are being used to prioritize natural products and designed compounds against EGFR and other cancer targets. Network pharmacology, QSAR, pharmacophore modeling and multi-omics increasingly add target and pathway context. Dual EGFR inhibitors and compounds affecting ferroptosis or EMT recur among the candidates. Most evidence remains computational, leaving biochemical and clinical validation as the main open step.

    26 papers · 20.6%

NEW DIRECTION

EGFR can serve as a non-signaling accessory antigen for CAR-T cells

Head and neck squamous cell carcinoma and EGFRvIII-specific CAR-T cells were the subject of the study by PMID 42811304. The usual constraint is that full-length EGFR cannot be used as a directly activating CAR target because it is expressed in normal tissues, whereas EGFRvIII is tumor-specific but often heterogeneous. The study instead found that an EGFR-binding non-signaling CAR, co-expressed with an EGFRvIII-specific signaling CAR, enhanced tumor-cell recognition and cytotoxicity. This gives EGFR a new therapeutic role as an accessory engagement antigen that strengthens another CAR’s response without itself providing the activation signal. 42811304Sep

Papers

The 126 papers from the last 6 months that study EGFR directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

EGFR-Targeted Solid Tumors (53)
  1. An Environmentally Sensitive Epidermal Growth Factor Receptor Probe for Turn-On Tumor Imaging and TGF-β1-Mediated Cancer Immunotherapy via the Selective Depletion of TI-Tregs. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018543
  2. A γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging. Molecular pharmaceutics · 2 Nov 2026 PMID 42969712
  3. PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma. Molecular pharmaceutics · 2 Nov 2026 PMID 42969702
  4. Antioxidant, anti-inflammatory, cytotoxicity and larvicidal activities of Ziziphus oenopolia leaves: in vitro and in silico studies. PloS one · 30 Oct 2026 PMID 42961863
  5. Case Report WIN-MTB-2024001 - WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR. Oncotarget · 16 Oct 2026 PMID 42885740
  6. Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
  7. Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma. BMC cancer · 29 Sept 2026 PMID 42811304
  8. From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells. PloS one · 16 Sept 2026 PMID 42748134
  9. Comprehensive trends in Chronic Kidney Disease prevalence and comorbidities across eGFR and albuminuria categories: a 20-year analysis of NHANES data. Renal failure · 15 Sept 2026 PMID 42736589
  10. Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
  11. The PROM1+SMAD5+ Tumor-Initiating Subpopulation Shapes Premetastatic Niches through Spatial Multi-Omics Landscapes in HER2-Positive Breast Cancer. Cancer communications (London, England) · 10 Sept 2026 PMID 42718887
  12. New oxa/thiadiazole-chalcone hybrids linked via a clickable 1,2,3-triazole bridge with dual EGFR/VEGFR-2 kinase inhibitory activity and antiproliferative effects. Bioorganic chemistry · 9 Sept 2026 PMID 42715623
  13. Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study. Journal for immunotherapy of cancer · 8 Sept 2026 PMID 42711069
  14. Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis. Scientific reports · 7 Sept 2026 PMID 42706361
  15. Identification of STK35L1 as a potential prognostic biomarker in breast carcinoma, and its expression exhibits high correlation with EGFR activity. Functional & integrative genomics · 4 Sept 2026 PMID 42696205
  16. HER2 and Other ErbB Receptors' Expression and Their Involvement in the Oncogenesis of Clear Cell Renal Cell Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674699
  17. DyAb: sequence-based antibody design and property prediction in a low-data regime. mAbs · 28 Aug 2026 PMID 42665538
  18. A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors. Science advances · 28 Aug 2026 PMID 42664321
  19. Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. Signal transduction and targeted therapy · 27 Aug 2026 PMID 42660909
  20. Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642931
  21. Integrated bulk and single-cell transcriptomic analyses identify senescence-related hub genes and microenvironmental remodeling in sarcopenia. Functional & integrative genomics · 26 Aug 2026 PMID 42642681
  22. EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 24 Aug 2026 PMID 42635595
  23. Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity. Clinical cancer research : an official journal of the American Association for Cancer Research · 21 Aug 2026 PMID 42627757
  24. Establishment and functional characterization of an EGFR-amplified tumoroid from squamous cell carcinoma of unknown primary. Human cell · 19 Aug 2026 PMID 42616271
  25. BLU-945 suppresses ABCB1-mediated drug efflux and restores chemosensitivity in multidrug-resistant cancer cells. European journal of pharmacology · 11 Aug 2026 PMID 42580505
  26. Suppression of EGFR signaling and drug-induced potentiation are widespread features of oncogenic RTK fusions. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574606
  27. Biomimetic exosomal delivery of ginsenoside Rd reduces post-stroke depression via microglial reprogramming in a pathway involving EGFR/JAK2/STAT3. Pharmacological research · 8 Aug 2026 PMID 42570766
  28. Design, synthesis and dual anticancer and antibacterial evaluation of novel 1,3,4-oxadiazole-2-thiol derivatives targeting EGFR and DNA Gyrase B: integrated docking, DFT and ADMET studies. Future medicinal chemistry · 6 Aug 2026 PMID 42558029
  29. A Single-Amino-Acid Ligand for LAT1: A Minimalist and Modular Platform for Lysosome-Targeted Degradation of Membrane Proteins. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 3 Aug 2026 PMID 42545113
  30. SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
  31. Near-infrared Photoimmunotherapy Targeting Canine Mammary Tumors: Comparative Oncology for Overcoming Human Breast Cancer. Anticancer research · 29 Jul 2026 PMID 42527083
  32. Mirabody-IR700: A novel EGFR-targeting platform for photoimmunotherapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jul 2026 PMID 42526257
  33. Cleavage-activatable antibody-photosensitizer conjugate enables tumor-selective photodynamic activation and immunogenic cell death. Journal of controlled release : official journal of the Controlled Release Society · 27 Jul 2026 PMID 42508768
  34. A Screening-Guided Biomimetic Exosome-Liposome Hybrid Nanoplatform Enables Pyroptosis-Enhanced Immune Reprogramming in Glioblastoma. ACS nano · 17 Jul 2026 PMID 42466899
  35. Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma. Bioorganic chemistry · 15 Jul 2026 PMID 42456413
  36. New indolin-2-one and isoindoline-1,3-dione derivatives as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro, in vivo, and in silico evaluation. Bioorganic chemistry · 13 Jul 2026 PMID 42442295
  37. Virtual screening-guided repurposing of fluorescent probes to detect EGFR expression in renal cells. Bioorganic chemistry · 10 Jul 2026 PMID 42430821
  38. EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma. Science translational medicine · 8 Jul 2026 PMID 42418561
  39. Exploring gefitinib to enhance endocytosis of antibodies and nucleic acid aptamers targeting EGFR in glioblastoma. Nanoscale · 2 Jul 2026 PMID 42390764
  40. SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy. Bioconjugate chemistry · 1 Jul 2026 PMID 42383853
  41. A single bioanalytical LC-MS/MS method for the quantification of pelitinib across biological matrices: An insight into in vitro metabolic stability, in vivo pharmacokinetics, and IVIVE. Journal of pharmaceutical and biomedical analysis · 30 Jun 2026 PMID 42378911
  42. Epigallocatechin Gallate Attenuates Arecoline-induced Migration and Invasion in Esophageal Squamous Cell Carcinoma Cells Associated With EGFR/AKT/P38 Signaling. Anticancer research · 29 Jun 2026 PMID 42373249
  43. Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials. European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372637
  44. A Platinum(IV) Metallo-Stapling Approach to Tumor-Specific Prodrugs for Targeted Chemo-Immunometabolic Cancer Therapy. Angewandte Chemie (International ed. in English) · 23 Jun 2026 PMID 42333893
  45. EGFR N-Glycosylation Catalyzed by NDST2 Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer research · 22 Jun 2026 PMID 42329862
  46. Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers. International journal of clinical oncology · 15 Jun 2026 PMID 42298055
  47. Dual-enzyme cascade protein hydrogel membrane orchestrates metabolism-immunity coupling for diabetic wound repair. Acta biomaterialia · 14 Jun 2026 PMID 42289263
  48. Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting 197gHg-Labeled Gold Nanoparticles. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 11 Jun 2026 PMID 42276782
  49. Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors. Journal of thrombosis and haemostasis : JTH · 6 Jun 2026 PMID 42250881
  50. Design, synthesis, and biological evaluation of novel ICA-II derivatives as anti-hepatocellular carcinoma agents targeting EGFR. European journal of medicinal chemistry · 4 Jun 2026 PMID 42241777
  51. Rosmarinic acid in Suhuang antitussive capsule alleviates cough variant asthma by targeting EGFR. Journal of ethnopharmacology · 3 Jun 2026 PMID 42235719
  52. Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 31 May 2026 PMID 42218660
  53. Pharmacological induction of mitochondria-lysosome hyper-tethering elicits synthetic lethality in glioblastoma. Cancer letters · 25 May 2026 PMID 42184920
EGFR-Mutant Lung Cancer (47)
  1. Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma. Journal of biomedical science · 12 Nov 2026 PMID 43021317
  2. Erlotinib Engineering Programs Tumor Targeting in an Atomically Precise Au8 Cluster. ACS nano · 20 Oct 2026 PMID 42899760
  3. Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations. Cancer cell · 16 Oct 2026 PMID 42887497
  4. Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer. PloS one · 8 Oct 2026 PMID 42848765
  5. In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC. Bioorganic chemistry · 7 Oct 2026 PMID 42843136
  6. Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management. Journal of neuro-oncology · 5 Oct 2026 PMID 42831966
  7. EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 3 Oct 2026 PMID 42829424
  8. Clinical Outcomes and Prognostic Factors of ABCP Therapy in EGFR-mutated NSCLC in the Osimertinib Era. Anticancer research · 1 Oct 2026 PMID 42823148
  9. In Silico Prioritization of Potential Protein Interactions for Glutathione-Responsive Abasic Site-Trapping Prodrugs in Non-Small Cell Lung Cancer. Journal of visualized experiments : JoVE · 30 Sept 2026 PMID 42813677
  10. Structure-based rational design and biological evaluation of a quinazoline-based EGFR exon 20 insertion inhibitor. Journal of enzyme inhibition and medicinal chemistry · 25 Sept 2026 PMID 42789311
  11. Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer. Science advances · 23 Sept 2026 PMID 42777032
  12. FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland. Acta oncologica (Stockholm, Sweden) · 23 Sept 2026 PMID 42776017
  13. Transcriptomic and network analyses identify epigenetic regulators of drug-tolerant persister (DTP) subsets in EGFR-mutant HCC827 non-small cell lung cancer. Genes & genomics · 15 Sept 2026 PMID 42742903
  14. Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
  15. EGFR-Degrading PROTACs and Calcium Peroxide Co-loaded Liposomes: Enabling EGFR Degradation and Hypoxia Alleviation as Dual Safeguards for NSCLC Therapy. ACS applied materials & interfaces · 1 Sept 2026 PMID 42679142
  16. Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation. Anticancer research · 31 Aug 2026 PMID 42674719
  17. Computational identification and evaluation of Adenium obesum phytochemicals as potential EGFR inhibitors for targeted therapy against non-small-cell lung cancer. PloS one · 31 Aug 2026 PMID 42672009
  18. Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01. Thoracic cancer · 31 Aug 2026 PMID 42670582
  19. The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
  20. Urea and carbamate-functionalized quinazolin-2,4-dione derivatives as EGFR tyrosine kinase inhibitors: synthesis, anticancer evaluation, molecular docking and molecular dynamics studies. Journal of computer-aided molecular design · 26 Aug 2026 PMID 42645656
  21. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology · 24 Aug 2026 PMID 42636833
  22. EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery. Cancer cell · 13 Aug 2026 PMID 42594872
  23. SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial. Cancer cell · 13 Aug 2026 PMID 42594871
  24. Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. Signal transduction and targeted therapy · 12 Aug 2026 PMID 42586967
  25. Novel 2-amino-4-(1H-imidazol)pyridine derivatives as potent brain-penetrant EGFR mutant inhibitors: Design, synthesis, biological evaluation, and molecular modeling study. Bioorganic chemistry · 6 Aug 2026 PMID 42561559
  26. BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Aug 2026 PMID 42546514
  27. Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study. Medicine · 31 Jul 2026 PMID 42536589
  28. JMJD5 promotes chemotherapy sensitivity of cisplatin in NSCLC by enhancing DNA damage. Biochemical and biophysical research communications · 19 Jul 2026 PMID 42472515
  29. Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Jul 2026 PMID 42446521
  30. Label-Free Prediction of EGFR Mutation Status Using Fluorescence Lifetime Imaging and Deep Learning in Lung Adenocarcinoma. Cancer research · 13 Jul 2026 PMID 42439806
  31. ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model. Lung cancer (Amsterdam, Netherlands) · 6 Jul 2026 PMID 42407241
  32. EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses. Cancer immunology, immunotherapy : CII · 3 Jul 2026 PMID 42397418
  33. Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene · 2 Jul 2026 PMID 42393288
  34. An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. Thoracic cancer · 1 Jul 2026 PMID 42381340
  35. MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer. Thoracic cancer · 1 Jul 2026 PMID 42381268
  36. High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial. Cell reports. Medicine · 30 Jun 2026 PMID 42379171
  37. Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer cell · 18 Jun 2026 PMID 42314664
  38. Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation. Science translational medicine · 17 Jun 2026 PMID 42308331
  39. Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer. International journal of cancer · 11 Jun 2026 PMID 42276818
  40. Landscape of Chinese Lung Cancer Patients With Compound Mutations and Acquired Resistance Alterations: A Retrospective Study. International journal of cancer · 4 Jun 2026 PMID 42237450
  41. Integrated isothermal shift assay and multi-omics identify melittin as a novel EGFR-targeting peptide to suppress NSCLC. Journal of translational medicine · 4 Jun 2026 PMID 42237319
  42. Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer. British journal of cancer · 2 Jun 2026 PMID 42231027
  43. Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
  44. The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib Therapy. Anticancer research · 27 May 2026 PMID 42203350
  45. Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH). Cancer biology & medicine · 22 May 2026 PMID 42170792
  46. Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer. CPT: pharmacometrics & systems pharmacology · 21 May 2026 PMID 42166539
  47. Identification of Key Genes and Clinical Feature Analyses of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma. Genetic testing and molecular biomarkers · 21 May 2026 PMID 42163810
Computational Drug Discovery (26)
  1. Design, Synthesis, and Biological Evaluation of Quinolin-2-One-Indole Schiff Base Hybrids as Potential EGFR-Targeted Anticancer Agents Against Breast and Ovarian Cancer. ChemMedChem · 20 Oct 2026 PMID 42897752
  2. A dual-functional antiviral and anticancer peptide to target intricate host-pathogen interacting proteins of human papillomavirus associated with head and neck cancer. PloS one · 9 Oct 2026 PMID 42853814
  3. DASH: A Pocket-Aware and Objective-Aware Framework for Million-Scale Structure-Based Molecular Generation. Journal of chemical information and modeling · 14 Sept 2026 PMID 42734526
  4. Atom-based 3D-QSAR, pharmacophore modelling and molecular dynamics guided identification of thienopyrimidinone derivatives targeting EGFR in breast cancer. Bioorganic chemistry · 12 Sept 2026 PMID 42731184
  5. Network pharmacology, and molecular docking studies for two flavonoid compounds isolated from Dodonaea viscosa towards SARS-CoV-2 infection and loaded in lipid nanoparticles. Artificial cells, nanomedicine, and biotechnology · 7 Sept 2026 PMID 42702742
  6. Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors. Bioorganic chemistry · 3 Sept 2026 PMID 42691879
  7. Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer. Molecular diversity · 28 Aug 2026 PMID 42665765
  8. Phycocyanobilin: A potential bioactive compound from Arthrospira platensis targeting LYN protein associated with systemic lupus erythematosus. PloS one · 28 Aug 2026 PMID 42664210
  9. Integrating network toxicology and transcriptomics to identify CXCL8, EGFR, PTPRC, MYC, and AKT1 as key targets of microplastic-induced miscarriage. Medicine · 22 Aug 2026 PMID 42629697
  10. Metabolomics-Driven Bioactivity-Guided Isolation and Molecular Docking Reveal Antibreast Cancer Metabolome Heterogeneity in Polygonum spp. Biomedical chromatography : BMC · 17 Aug 2026 PMID 42605931
  11. Active ingredients and molecular targets of Tripterygium wilfordii against colorectal cancer: network pharmacology, molecular docking, molecular dynamics simulations and in vitro evaluation. Journal of computer-aided molecular design · 14 Aug 2026 PMID 42595923
  12. Molecular modeling study on the binding mechanisms of third-generation EGFR inhibitor Lazertinib. Journal of molecular graphics & modelling · 25 Jul 2026 PMID 42501674
  13. DF-S4: Disentangled FiLM-Conditioned Molecular Generation Using the S4 Architecture. Journal of chemical information and modeling · 23 Jul 2026 PMID 42489643
  14. Evaluation of Itraconazole as a repurposed small molecule inhibitor of EMT in breast cancer: a molecular docking and dynamics study. Journal of molecular modeling · 18 Jul 2026 PMID 42470490
  15. Revealing the mechanism of heptamethoxyflavone against diabetic kidney disease: an integrated study combining network pharmacology, molecular docking and experimental validation. Biochemical and biophysical research communications · 13 Jul 2026 PMID 42442088
  16. Unveiling Large-Scale Kinase-Centric Protein-Protein Interactions through a Knowledge-Informed Workflow. Journal of chemical information and modeling · 10 Jul 2026 PMID 42427025
  17. Cryptotanshinone Targets Ferroptosis in Glioma via the EGFR/ROS Signaling Pathway. Neurochemical research · 25 Jun 2026 PMID 42348047
  18. Multi-omics investigation of per- and polyfluoroalkyl substances in lung adenocarcinoma: comprehensive network toxicology, machine learning and molecular docking experiments. Molecular diversity · 23 Jun 2026 PMID 42334505
  19. Identification of chemical components in Thalictrum glandulosissimum using UPLC-Q-TOF-MS/MS and pharmacokinetic analysis of multiple alkaloids in normal and ulcerative colitis rats. Journal of pharmaceutical and biomedical analysis · 22 Jun 2026 PMID 42330697
  20. Network pharmacology, molecular docking, and dynamics simulation of 7-phenyl-5-(p-tolyl)pyrido[2,3-d] pyrimidine-4-amine as anticancer agents with multitarget inhibitory action. Computers in biology and medicine · 3 Jun 2026 PMID 42235269
  21. Rationally designed quinazolinone derivatives incorporating acetyl pyridine and thiazole scaffolds as dual EGFR/HER-2 anticancer agents: integrated biological evaluation, molecular profiling, and advanced computational studies. Bioorganic chemistry · 30 May 2026 PMID 42217499
  22. From Bacteria to Breakthroughs: Design and Evaluation of Gallocin-Based Peptide for Colorectal Cancer Therapeutic. Probiotics and antimicrobial proteins · 30 May 2026 PMID 42217153
  23. Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
  24. Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. Drug development research · 27 May 2026 PMID 42200498
  25. Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-a]quinoxalines as dual EGFR and tubulin targeting anticancer agents. Journal of enzyme inhibition and medicinal chemistry · 25 May 2026 PMID 42179048
  26. Discovery of new quinazolin-4-ones as dual EGFR/c-SRC inhibitors with potential to overcome bypass-mediated resistance in cancer. European journal of medicinal chemistry · 21 May 2026 PMID 42166815

By study type

Clinical trials (11)
  1. Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations. Cancer cell · 16 Oct 2026 PMID 42887497
  2. Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for immunotherapy of cancer · 12 Sept 2026 PMID 42731876
  3. Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study. Journal for immunotherapy of cancer · 8 Sept 2026 PMID 42711069
  4. Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. Signal transduction and targeted therapy · 27 Aug 2026 PMID 42660909
  5. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology · 24 Aug 2026 PMID 42636833
  6. EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 24 Aug 2026 PMID 42635595
  7. SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial. Cancer cell · 13 Aug 2026 PMID 42594871
  8. Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study. Signal transduction and targeted therapy · 12 Aug 2026 PMID 42586967
  9. An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib. Thoracic cancer · 1 Jul 2026 PMID 42381340
  10. High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial. Cell reports. Medicine · 30 Jun 2026 PMID 42379171
  11. Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 31 May 2026 PMID 42218660
Observational studies and case reports (14)
  1. Case Report WIN-MTB-2024001 - WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR. Oncotarget · 16 Oct 2026 PMID 42885740
  2. Predictive modeling of lung cancer subtype with integration of clinical and thoracic imaging features to guide early brain metastasis management. Journal of neuro-oncology · 5 Oct 2026 PMID 42831966
  3. Clinical Outcomes and Prognostic Factors of ABCP Therapy in EGFR-mutated NSCLC in the Osimertinib Era. Anticancer research · 1 Oct 2026 PMID 42823148
  4. FIN-EGFR: real-world treatment outcomes by EGFR mutational subtypes in NSCLC in Southern Finland. Acta oncologica (Stockholm, Sweden) · 23 Sept 2026 PMID 42776017
  5. Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
  6. Association Between EGFR Mutation Status and Out-of-field Recurrence in Locally Advanced Unresectable Non-small Cell Lung Cancer Treated With Chemoradiotherapy and Durvalumab Consolidation. Anticancer research · 31 Aug 2026 PMID 42674719
  7. Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity. Clinical cancer research : an official journal of the American Association for Cancer Research · 21 Aug 2026 PMID 42627757
  8. BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Aug 2026 PMID 42546514
  9. Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study. Medicine · 31 Jul 2026 PMID 42536589
  10. Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer. International journal of cancer · 11 Jun 2026 PMID 42276818
  11. Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors. Journal of thrombosis and haemostasis : JTH · 6 Jun 2026 PMID 42250881
  12. Landscape of Chinese Lung Cancer Patients With Compound Mutations and Acquired Resistance Alterations: A Retrospective Study. International journal of cancer · 4 Jun 2026 PMID 42237450
  13. Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer. British journal of cancer · 2 Jun 2026 PMID 42231027
  14. The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib Therapy. Anticancer research · 27 May 2026 PMID 42203350
Human data, design not indexed (23)
  1. A dual-functional antiviral and anticancer peptide to target intricate host-pathogen interacting proteins of human papillomavirus associated with head and neck cancer. PloS one · 9 Oct 2026 PMID 42853814
  2. In Silico Prioritization of Potential Protein Interactions for Glutathione-Responsive Abasic Site-Trapping Prodrugs in Non-Small Cell Lung Cancer. Journal of visualized experiments : JoVE · 30 Sept 2026 PMID 42813677
  3. Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer. The journal of pathology. Clinical research · 30 Sept 2026 PMID 42811483
  4. Structure-based rational design and biological evaluation of a quinazoline-based EGFR exon 20 insertion inhibitor. Journal of enzyme inhibition and medicinal chemistry · 25 Sept 2026 PMID 42789311
  5. Comprehensive trends in Chronic Kidney Disease prevalence and comorbidities across eGFR and albuminuria categories: a 20-year analysis of NHANES data. Renal failure · 15 Sept 2026 PMID 42736589
  6. Atom-based 3D-QSAR, pharmacophore modelling and molecular dynamics guided identification of thienopyrimidinone derivatives targeting EGFR in breast cancer. Bioorganic chemistry · 12 Sept 2026 PMID 42731184
  7. Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01. Thoracic cancer · 31 Aug 2026 PMID 42670582
  8. DyAb: sequence-based antibody design and property prediction in a low-data regime. mAbs · 28 Aug 2026 PMID 42665538
  9. Phycocyanobilin: A potential bioactive compound from Arthrospira platensis targeting LYN protein associated with systemic lupus erythematosus. PloS one · 28 Aug 2026 PMID 42664210
  10. The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
  11. Integrating network toxicology and transcriptomics to identify CXCL8, EGFR, PTPRC, MYC, and AKT1 as key targets of microplastic-induced miscarriage. Medicine · 22 Aug 2026 PMID 42629697
  12. SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
  13. Molecular modeling study on the binding mechanisms of third-generation EGFR inhibitor Lazertinib. Journal of molecular graphics & modelling · 25 Jul 2026 PMID 42501674
  14. Evaluation of Itraconazole as a repurposed small molecule inhibitor of EMT in breast cancer: a molecular docking and dynamics study. Journal of molecular modeling · 18 Jul 2026 PMID 42470490
  15. Clinical Significance of EGFR Amplification in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Receiving First-line Osimertinib. Clinical cancer research : an official journal of the American Association for Cancer Research · 14 Jul 2026 PMID 42446521
  16. Label-Free Prediction of EGFR Mutation Status Using Fluorescence Lifetime Imaging and Deep Learning in Lung Adenocarcinoma. Cancer research · 13 Jul 2026 PMID 42439806
  17. Virtual screening-guided repurposing of fluorescent probes to detect EGFR expression in renal cells. Bioorganic chemistry · 10 Jul 2026 PMID 42430821
  18. Unveiling Large-Scale Kinase-Centric Protein-Protein Interactions through a Knowledge-Informed Workflow. Journal of chemical information and modeling · 10 Jul 2026 PMID 42427025
  19. Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials. European journal of cancer (Oxford, England : 1990) · 29 Jun 2026 PMID 42372637
  20. Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers. International journal of clinical oncology · 15 Jun 2026 PMID 42298055
  21. Network pharmacology, molecular docking, and dynamics simulation of 7-phenyl-5-(p-tolyl)pyrido[2,3-d] pyrimidine-4-amine as anticancer agents with multitarget inhibitory action. Computers in biology and medicine · 3 Jun 2026 PMID 42235269
  22. Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer. CPT: pharmacometrics & systems pharmacology · 21 May 2026 PMID 42166539
  23. Identification of Key Genes and Clinical Feature Analyses of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma. Genetic testing and molecular biomarkers · 21 May 2026 PMID 42163810
Preclinical: animal, cell and lab studies (72)
  1. Repurposing of abemaciclib to overcome C797S-mediated osimertinib resistance in EGFR-mutant lung adenocarcinoma. Journal of biomedical science · 12 Nov 2026 PMID 43021317
  2. An Environmentally Sensitive Epidermal Growth Factor Receptor Probe for Turn-On Tumor Imaging and TGF-β1-Mediated Cancer Immunotherapy via the Selective Depletion of TI-Tregs. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018543
  3. A γ-AApeptide-Based Antibody-like Peptidomimetic for Enhanced EGFR-Targeted PET Imaging. Molecular pharmaceutics · 2 Nov 2026 PMID 42969712
  4. PIP3 and EGFR Dual Targeting for the Development of a Polypeptide Complex Drug Aimed at the Specific Delivery and Therapy of Anaplastic Thyroid Carcinoma. Molecular pharmaceutics · 2 Nov 2026 PMID 42969702
  5. Antioxidant, anti-inflammatory, cytotoxicity and larvicidal activities of Ziziphus oenopolia leaves: in vitro and in silico studies. PloS one · 30 Oct 2026 PMID 42961863
  6. Erlotinib Engineering Programs Tumor Targeting in an Atomically Precise Au8 Cluster. ACS nano · 20 Oct 2026 PMID 42899760
  7. Design, Synthesis, and Biological Evaluation of Quinolin-2-One-Indole Schiff Base Hybrids as Potential EGFR-Targeted Anticancer Agents Against Breast and Ovarian Cancer. ChemMedChem · 20 Oct 2026 PMID 42897752
  8. Dual targeting of EGFR signaling and microtubule dynamics enhances replication-associated cellular stress and suppresses tumor growth in gefitinib-resistant non-small cell lung cancer. PloS one · 8 Oct 2026 PMID 42848765
  9. In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC. Bioorganic chemistry · 7 Oct 2026 PMID 42843136
  10. Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma. BMC cancer · 29 Sept 2026 PMID 42811304
  11. Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer. Science advances · 23 Sept 2026 PMID 42777032
  12. From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells. PloS one · 16 Sept 2026 PMID 42748134
  13. Transcriptomic and network analyses identify epigenetic regulators of drug-tolerant persister (DTP) subsets in EGFR-mutant HCC827 non-small cell lung cancer. Genes & genomics · 15 Sept 2026 PMID 42742903
  14. DASH: A Pocket-Aware and Objective-Aware Framework for Million-Scale Structure-Based Molecular Generation. Journal of chemical information and modeling · 14 Sept 2026 PMID 42734526
  15. The PROM1+SMAD5+ Tumor-Initiating Subpopulation Shapes Premetastatic Niches through Spatial Multi-Omics Landscapes in HER2-Positive Breast Cancer. Cancer communications (London, England) · 10 Sept 2026 PMID 42718887
  16. New oxa/thiadiazole-chalcone hybrids linked via a clickable 1,2,3-triazole bridge with dual EGFR/VEGFR-2 kinase inhibitory activity and antiproliferative effects. Bioorganic chemistry · 9 Sept 2026 PMID 42715623
  17. Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis. Scientific reports · 7 Sept 2026 PMID 42706361
  18. Network pharmacology, and molecular docking studies for two flavonoid compounds isolated from Dodonaea viscosa towards SARS-CoV-2 infection and loaded in lipid nanoparticles. Artificial cells, nanomedicine, and biotechnology · 7 Sept 2026 PMID 42702742
  19. Identification of STK35L1 as a potential prognostic biomarker in breast carcinoma, and its expression exhibits high correlation with EGFR activity. Functional & integrative genomics · 4 Sept 2026 PMID 42696205
  20. Design, synthesis, molecular docking, ADMET and anticancer evaluation of novel pyridine/thiazole hybrids as dual VEGFR-2 and EGFR kinase inhibitors. Bioorganic chemistry · 3 Sept 2026 PMID 42691879
  21. EGFR-Degrading PROTACs and Calcium Peroxide Co-loaded Liposomes: Enabling EGFR Degradation and Hypoxia Alleviation as Dual Safeguards for NSCLC Therapy. ACS applied materials & interfaces · 1 Sept 2026 PMID 42679142
  22. HER2 and Other ErbB Receptors' Expression and Their Involvement in the Oncogenesis of Clear Cell Renal Cell Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674699
  23. Computational identification and evaluation of Adenium obesum phytochemicals as potential EGFR inhibitors for targeted therapy against non-small-cell lung cancer. PloS one · 31 Aug 2026 PMID 42672009
  24. A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors. Science advances · 28 Aug 2026 PMID 42664321
  25. Urea and carbamate-functionalized quinazolin-2,4-dione derivatives as EGFR tyrosine kinase inhibitors: synthesis, anticancer evaluation, molecular docking and molecular dynamics studies. Journal of computer-aided molecular design · 26 Aug 2026 PMID 42645656
  26. Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642931
  27. Integrated bulk and single-cell transcriptomic analyses identify senescence-related hub genes and microenvironmental remodeling in sarcopenia. Functional & integrative genomics · 26 Aug 2026 PMID 42642681
  28. Establishment and functional characterization of an EGFR-amplified tumoroid from squamous cell carcinoma of unknown primary. Human cell · 19 Aug 2026 PMID 42616271
  29. Metabolomics-Driven Bioactivity-Guided Isolation and Molecular Docking Reveal Antibreast Cancer Metabolome Heterogeneity in Polygonum spp. Biomedical chromatography : BMC · 17 Aug 2026 PMID 42605931
  30. Active ingredients and molecular targets of Tripterygium wilfordii against colorectal cancer: network pharmacology, molecular docking, molecular dynamics simulations and in vitro evaluation. Journal of computer-aided molecular design · 14 Aug 2026 PMID 42595923
  31. EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery. Cancer cell · 13 Aug 2026 PMID 42594872
  32. BLU-945 suppresses ABCB1-mediated drug efflux and restores chemosensitivity in multidrug-resistant cancer cells. European journal of pharmacology · 11 Aug 2026 PMID 42580505
  33. Suppression of EGFR signaling and drug-induced potentiation are widespread features of oncogenic RTK fusions. Proceedings of the National Academy of Sciences of the United States of America · 10 Aug 2026 PMID 42574606
  34. Biomimetic exosomal delivery of ginsenoside Rd reduces post-stroke depression via microglial reprogramming in a pathway involving EGFR/JAK2/STAT3. Pharmacological research · 8 Aug 2026 PMID 42570766
  35. Novel 2-amino-4-(1H-imidazol)pyridine derivatives as potent brain-penetrant EGFR mutant inhibitors: Design, synthesis, biological evaluation, and molecular modeling study. Bioorganic chemistry · 6 Aug 2026 PMID 42561559
  36. Design, synthesis and dual anticancer and antibacterial evaluation of novel 1,3,4-oxadiazole-2-thiol derivatives targeting EGFR and DNA Gyrase B: integrated docking, DFT and ADMET studies. Future medicinal chemistry · 6 Aug 2026 PMID 42558029
  37. Near-infrared Photoimmunotherapy Targeting Canine Mammary Tumors: Comparative Oncology for Overcoming Human Breast Cancer. Anticancer research · 29 Jul 2026 PMID 42527083
  38. Mirabody-IR700: A novel EGFR-targeting platform for photoimmunotherapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jul 2026 PMID 42526257
  39. Cleavage-activatable antibody-photosensitizer conjugate enables tumor-selective photodynamic activation and immunogenic cell death. Journal of controlled release : official journal of the Controlled Release Society · 27 Jul 2026 PMID 42508768
  40. DF-S4: Disentangled FiLM-Conditioned Molecular Generation Using the S4 Architecture. Journal of chemical information and modeling · 23 Jul 2026 PMID 42489643
  41. JMJD5 promotes chemotherapy sensitivity of cisplatin in NSCLC by enhancing DNA damage. Biochemical and biophysical research communications · 19 Jul 2026 PMID 42472515
  42. A Screening-Guided Biomimetic Exosome-Liposome Hybrid Nanoplatform Enables Pyroptosis-Enhanced Immune Reprogramming in Glioblastoma. ACS nano · 17 Jul 2026 PMID 42466899
  43. Brigatinib-based targeted drug conjugates afford selective and potent anti-tumor efficacy in the treatment of pancreatic ductal adenocarcinoma. Bioorganic chemistry · 15 Jul 2026 PMID 42456413
  44. New indolin-2-one and isoindoline-1,3-dione derivatives as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro, in vivo, and in silico evaluation. Bioorganic chemistry · 13 Jul 2026 PMID 42442295
  45. Revealing the mechanism of heptamethoxyflavone against diabetic kidney disease: an integrated study combining network pharmacology, molecular docking and experimental validation. Biochemical and biophysical research communications · 13 Jul 2026 PMID 42442088
  46. EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma. Science translational medicine · 8 Jul 2026 PMID 42418561
  47. ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model. Lung cancer (Amsterdam, Netherlands) · 6 Jul 2026 PMID 42407241
  48. EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses. Cancer immunology, immunotherapy : CII · 3 Jul 2026 PMID 42397418
  49. Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene · 2 Jul 2026 PMID 42393288
  50. Exploring gefitinib to enhance endocytosis of antibodies and nucleic acid aptamers targeting EGFR in glioblastoma. Nanoscale · 2 Jul 2026 PMID 42390764
  51. SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy. Bioconjugate chemistry · 1 Jul 2026 PMID 42383853
  52. MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib-Resistant MET-Amplified, EGFR-Mutated Non-Small Cell Lung Cancer. Thoracic cancer · 1 Jul 2026 PMID 42381268
  53. A single bioanalytical LC-MS/MS method for the quantification of pelitinib across biological matrices: An insight into in vitro metabolic stability, in vivo pharmacokinetics, and IVIVE. Journal of pharmaceutical and biomedical analysis · 30 Jun 2026 PMID 42378911
  54. Epigallocatechin Gallate Attenuates Arecoline-induced Migration and Invasion in Esophageal Squamous Cell Carcinoma Cells Associated With EGFR/AKT/P38 Signaling. Anticancer research · 29 Jun 2026 PMID 42373249
  55. Cryptotanshinone Targets Ferroptosis in Glioma via the EGFR/ROS Signaling Pathway. Neurochemical research · 25 Jun 2026 PMID 42348047
  56. A Platinum(IV) Metallo-Stapling Approach to Tumor-Specific Prodrugs for Targeted Chemo-Immunometabolic Cancer Therapy. Angewandte Chemie (International ed. in English) · 23 Jun 2026 PMID 42333893
  57. Identification of chemical components in Thalictrum glandulosissimum using UPLC-Q-TOF-MS/MS and pharmacokinetic analysis of multiple alkaloids in normal and ulcerative colitis rats. Journal of pharmaceutical and biomedical analysis · 22 Jun 2026 PMID 42330697
  58. EGFR N-Glycosylation Catalyzed by NDST2 Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer research · 22 Jun 2026 PMID 42329862
  59. Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer cell · 18 Jun 2026 PMID 42314664
  60. Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation. Science translational medicine · 17 Jun 2026 PMID 42308331
  61. Dual-enzyme cascade protein hydrogel membrane orchestrates metabolism-immunity coupling for diabetic wound repair. Acta biomaterialia · 14 Jun 2026 PMID 42289263
  62. Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting 197gHg-Labeled Gold Nanoparticles. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 11 Jun 2026 PMID 42276782
  63. Design, synthesis, and biological evaluation of novel ICA-II derivatives as anti-hepatocellular carcinoma agents targeting EGFR. European journal of medicinal chemistry · 4 Jun 2026 PMID 42241777
  64. Rosmarinic acid in Suhuang antitussive capsule alleviates cough variant asthma by targeting EGFR. Journal of ethnopharmacology · 3 Jun 2026 PMID 42235719
  65. Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
  66. Rationally designed quinazolinone derivatives incorporating acetyl pyridine and thiazole scaffolds as dual EGFR/HER-2 anticancer agents: integrated biological evaluation, molecular profiling, and advanced computational studies. Bioorganic chemistry · 30 May 2026 PMID 42217499
  67. From Bacteria to Breakthroughs: Design and Evaluation of Gallocin-Based Peptide for Colorectal Cancer Therapeutic. Probiotics and antimicrobial proteins · 30 May 2026 PMID 42217153
  68. Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
  69. Lead Discovery via Scaffold Refinement: Structure-Guided Optimization of 1,2,4-Triazolo[1,5-a]Pyrimidines as Potent Dual EGFR/CDK-2 Inhibitors Targeting Colorectal Carcinoma. Drug development research · 27 May 2026 PMID 42200498
  70. Pharmacological induction of mitochondria-lysosome hyper-tethering elicits synthetic lethality in glioblastoma. Cancer letters · 25 May 2026 PMID 42184920
  71. Design and Pictet-Spengler enabled synthesis of carboxamide-substituted imidazo[1,2-a]quinoxalines as dual EGFR and tubulin targeting anticancer agents. Journal of enzyme inhibition and medicinal chemistry · 25 May 2026 PMID 42179048
  72. Discovery of new quinazolin-4-ones as dual EGFR/c-SRC inhibitors with potential to overcome bypass-mediated resistance in cancer. European journal of medicinal chemistry · 21 May 2026 PMID 42166815
Unclassified: not yet indexed with MeSH (6)
  1. EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 3 Oct 2026 PMID 42829424
  2. Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer. Molecular diversity · 28 Aug 2026 PMID 42665765
  3. A Single-Amino-Acid Ligand for LAT1: A Minimalist and Modular Platform for Lysosome-Targeted Degradation of Membrane Proteins. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 3 Aug 2026 PMID 42545113
  4. Multi-omics investigation of per- and polyfluoroalkyl substances in lung adenocarcinoma: comprehensive network toxicology, machine learning and molecular docking experiments. Molecular diversity · 23 Jun 2026 PMID 42334505
  5. Integrated isothermal shift assay and multi-omics identify melittin as a novel EGFR-targeting peptide to suppress NSCLC. Journal of translational medicine · 4 Jun 2026 PMID 42237319
  6. Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH). Cancer biology & medicine · 22 May 2026 PMID 42170792